Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Hoffman

Showing results (1031-1040 of 1,048) with videos related to

Pageof 105
Sort By:
JAMA Network Open|January 25, 2022
Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension TrialJean K Mah, Paula R Clemens, Michela Guglieri, et al.
Human Genetics|November 10, 2010
AKT1 polymorphisms are associated with risk for metabolic syndromeJoseph M Devaney, Heather Gordish-Dressman, Brennan T Harmon, et al.
Neurology|August 28, 2019
Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle functionEric P Hoffman, Benjamin D Schwartz, Laurel J Mengle-Gaw, et al.
Journal of Neuromuscular Diseases|February 16, 2024
The IAAM LTBP4 Haplotype is Protective Against Dystrophin-Deficient CardiomyopathyLuca Bello, Daniele Sabbatini, Aurora Fusto, et al.
Neurology|June 30, 2012
Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophyLuca Bello, Luisa Piva, Andrea Barp, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 9, 2012
Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN GuidelinesMargaret A Tempero, J Pablo Arnoletti, Stephen W Behrman, et al.
Annals of Clinical and Translational Neurology|April 29, 2020
Genetic modifiers of respiratory function in Duchenne muscular dystrophyLuca Bello, Grazia D'Angelo, Matteo Villa, et al.
Pharmacological Research|September 17, 2018
Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drugLaurie S Conklin, Jesse M Damsker, Eric P Hoffman, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 8, 2014
Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelinesMargaret A Tempero, Mokenge P Malafa, Stephen W Behrman, et al.
Neurology|February 9, 2024
Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy: A Randomized Controlled TrialUtkarsh J Dang, Jesse M Damsker, Michela Guglieri, et al.
Pageof 105

Showing results (1031-1040 of 1,048) with videos related to

Sort By:
Pageof 105
JAMA Network Open|January 25, 2022
Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension TrialJean K Mah, Paula R Clemens, Michela Guglieri, et al.
Human Genetics|November 10, 2010
AKT1 polymorphisms are associated with risk for metabolic syndromeJoseph M Devaney, Heather Gordish-Dressman, Brennan T Harmon, et al.
Neurology|August 28, 2019
Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle functionEric P Hoffman, Benjamin D Schwartz, Laurel J Mengle-Gaw, et al.
Journal of Neuromuscular Diseases|February 16, 2024
The IAAM LTBP4 Haplotype is Protective Against Dystrophin-Deficient CardiomyopathyLuca Bello, Daniele Sabbatini, Aurora Fusto, et al.
Neurology|June 30, 2012
Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophyLuca Bello, Luisa Piva, Andrea Barp, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 9, 2012
Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN GuidelinesMargaret A Tempero, J Pablo Arnoletti, Stephen W Behrman, et al.
Annals of Clinical and Translational Neurology|April 29, 2020
Genetic modifiers of respiratory function in Duchenne muscular dystrophyLuca Bello, Grazia D'Angelo, Matteo Villa, et al.
Pharmacological Research|September 17, 2018
Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drugLaurie S Conklin, Jesse M Damsker, Eric P Hoffman, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 8, 2014
Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelinesMargaret A Tempero, Mokenge P Malafa, Stephen W Behrman, et al.
Neurology|February 9, 2024
Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy: A Randomized Controlled TrialUtkarsh J Dang, Jesse M Damsker, Michela Guglieri, et al.
Pageof 105